However, when STZ is administered at low doses during 5 consecutive days, it induces mild type 1 diabetes, through a T-lymphocyte-dependent process, an autoimmune destruction of pancreatic β cells mediated by both CD4+ and CD8+ T cells [24,34]. The gene discussed is CD8A; the disease is type 1 diabetes mellitus.